Regenerative Medicine Market worth $62.69 billion by 2031
The report "Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogeneic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031", is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period. The global regenerative medicine market is experiencing strong growth, driven by the increasing focus on personalized medicine, expanding applications across chronic and rare diseases, rising partnerships among therapy developers, and continued investment in advanced cell, gene, and tissue-engineered therapies.
Browse 297 market data Tables and 57 Figures spread through 295 Pages and in-depth TOC on "Regenerative Medicine Market by Product (Stem Cell [Autologous, Allogeneic], Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html
The cell therapy segment accounted for the largest share of the regenerative medicine market.
Based on product, the regenerative medicine market is segmented into cell therapy, gene therapy, and tissue engineering. Cell therapy includes stem cell therapy, cell transplantations, stem cell therapy products such as autologous and allogeneic therapies, and cell-based immunotherapy products. Expanding adoption of CAR-T and other cellular therapies, increasing stem cell applications, growing treatment-center capabilities, and continued regulatory approvals are supporting the segment's growth. Gene therapy and tissue engineering are also gaining momentum as developers broaden disease targets and advance regenerative approaches for tissue repair and functional restoration.
The musculoskeletal disorder segment accounts for the largest share of the regenerative medicine market.
By therapeutic area, the regenerative medicines market covers oncology, musculoskeletal disorders, dermatology & wound care, cardiovascular diseases, ophthalmology, neurology, and other applications. Musculoskeletal applications remain important due to the high burden of orthopedic disorders, cartilage and bone injuries, and growing research into regenerative approaches for tissue repair. At the same time, cell-based immunotherapies continue to expand in oncology, while gene therapies are broadening treatment options in neurological and ophthalmic diseases. Tissue-engineered products are gaining use in wound care and reconstructive applications.
North America dominated the global regenerative medicine market in 2025.
North America accounts for the largest share of the global regenerative medicine market, closely followed by Europe and Asia Pacific. This can be attributed to the growth of stem cell research, healthcare sector expansion, and the increase in the adoption of stem cell therapy and cell immunotherapies for cancer and other chronic disease treatment.
The global regenerative medicine market comprises many key market players, such as Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Vericel Corporation (US), MIMEDX Group, Inc. (US), Organogenesis Inc. (US), Medtronic plc (Ireland), and Bristol-Myers Squibb Company (US).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Regenerative Medicine Market
- What will your New Revenue Sources be
- Who will be your Top Customer; what will make them switch
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
